{"schema_version":"secwatch.filing_event.v1","accession":"0001040130-24-000065","form_type":"8-K","ticker":"PETS","cik":"0001040130","company_name":"PETMED EXPRESS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.978758+00:00","generated_at":"2026-05-31T12:05:39.727622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PetMed Express Q1 net income $3.8M on $8.7M stock comp reversal; sales down 13%","bullets":["Net sales $68M, down 13% YoY; net income $3.8M ($0.18 diluted) vs loss of $(1.1M) ($(0.06)) prior year.","Net income increase driven by $8.7M reversal of stock compensation expense from former CEO departure.","Adjusted EBITDA $(1.5M), $4.9M lower than prior year, due to lower sales and gross profit.","New CEO Sandra Campos, plus CMO, COO, CDTO appointed; cost reduction and operational streamlining underway.","Management sees Q1 as transition quarter; early positive indicators from customer growth strategies."],"urls":{"canonical":"https://secwatch.observer/filing/0001040130-24-000065","json":"https://secwatch.observer/filing/0001040130-24-000065.json","markdown":"https://secwatch.observer/filing/0001040130-24-000065.md","text":"https://secwatch.observer/filing/0001040130-24-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000065/0001040130-24-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1040130/000104013024000065/pets-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:05:39.727622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}